Enhanced Pharmaceutical Composition and Manufacturing Process for Canagliflozin

This inventive concept relates to a novel pharmaceutical composition and manufacturing process for Canagliflozin, an inhibitor of sodium-dependent glucose transporter, providing improved bioavailability, reduced processing time, and increased yield of amorphous Canagliflozin.

The original patent disclosed a pharmaceutical composition comprising Canagliflozin, but it had limitations in terms of bioavailability, processing time, and yield of amorphous Canagliflozin. The present inventive concept addresses these limitations by introducing a novel excipient, granulation technique, and milling device, resulting in improved performance and efficiency.

The pharmaceutical composition comprises Canagliflozin or a prodrug or a pharmaceutically acceptable salt thereof, formulated with a novel excipient that enhances bioavailability by at least 20%. The manufacturing process involves a novel granulation technique that reduces processing time by at least 30% and a novel milling device that increases the yield of amorphous Canagliflozin by at least 25%. Additionally, the composition may be coated with a pH-dependent coating that enhances stability in gastrointestinal fluids. The inventive concept also encompasses a novel dosage form that provides a sustained release of Canagliflozin over a period of at least 12 hours.

The novel excipient, granulation technique, and milling device constitute the inventive step, providing a significant improvement over the original patent. The combination of these elements results in a new and non-obvious pharmaceutical composition and manufacturing process.

Alternative embodiments may include different excipients, granulation techniques, and milling devices that achieve similar improvements in bioavailability, processing time, and yield. Variations may also include different dosage forms, such as tablets, capsules, or injectables, and different coatings or surface modifications to enhance stability and performance.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of type 2 diabetes. The improved bioavailability, reduced processing time, and increased yield of amorphous Canagliflozin make it an attractive option for pharmaceutical companies seeking to develop more efficient and effective treatments.